stockrow
Saturday 7 November 2026
Export ANL’s income statement to Excel — free account
Adlai Nortye Ltd. Sponsored ADR
Adlai Nortye Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.0 million, roughly unchanged from fiscal 2023.
10.34
0.66
+6.82%
Follow ANL
Alert me
Adlai Nortye Ltd. Sponsored ADR (ANL) P/E ratio
P/E ratio, daily
Annual newest first
| Period | P/E ratio | Change |
|---|
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OLMA Olema Pharmaceuticals, Inc. compare | n/m |
| BCAX Bicara Therapeutics Inc. compare | n/m |
| NVCT Nuvectis Pharma, Inc. compare | n/m |
| ACRS Aclaris Therapeutics, Inc. compare | n/m |
| IMMX Immix Biopharma, Inc. compare | n/m |
| APMD Apnimed, Inc. compare | 0.8× |
| ANL Adlai Nortye Ltd. Sponsored ADR | — |
| OBX Obsidian Therapeutics, Inc compare | — |
| IAM Iambic Therapeutics, Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)